Back to Search Results

Diagnosis and Management of Cervical Ectopic Pregnancy

1/1/2014 - Paula Amato, MD

Editor:  Vanessa Gregg. MD

 

Cervical ectopic pregnancy is the rare implantation of a pregnancy in the endocervical canal and accounts for less than 1% of all ectopic pregnancies. Patients usually present with vaginal bleeding, which can be profuse and is often painless. Other clinical signs may include a soft, disproportionately large cervix and an hourglass-shaped uterus. If a physical exam is performed, the cervix may be bigger than the uterine fundus. The differential diagnosis also includes incomplete abortion and pregnancy implanted in a cesarean or hysterotomy scar.

Transvaginal ultrasound is an important component of the diagnosis. Sonographic criteria include an empty uterus, an enlarged barrel-shaped cervix, a gestational sac within the cervical canal with or without cardiac activity, peritrophoblastic Doppler blood flow to the cervix, and an absent “sliding sign” (the intracervical sac fails to slide along the cervical canal when gentle pressure is applied to the cervix with the vaginal transducer). The presence of cardiac activity or peritrophoblastic blood flow to the cervix is strongly suggestive of a cervical ectopic pregnancy. Once cervical pregnancy is thought likely, bimanual examination should be avoided.

Early diagnosis and treatment is critical to avoid serious complications such as severe hemorrhage and the need for hysterectomy. The most appropriate treatment depends on the clinical presentation. If the patient is hemodynamically stable, medical management with systemic single dose or multi-dose methotrexate (MTX) is the therapy of choice. The risk of MTX failure must be weighed against the significant risk of hemorrhage with surgical management of cervical pregnancies. MTX may be administered for cervical pregnancy in the presence of factors such as cardiac activity, advanced gestational age, a gestational sac >4 cm, and βhCG level >5,000 mIU/ml, which are relative contraindications to its use for tubal ectopic pregnancy.

If fetal cardiac activity is present, intra-amniotic injection of potassium chloride injection has been associated with successful avoidance of hysterectomy in 80% of cases. Dilation and curettage carries a significant risk of severe hemorrhage. Preoperative uterine artery embolization (UAE) may be useful to help control hemorrhage or in the management of bleeding complications.

In patients who are hemodynamically unstable or fail medical management, surgical therapy is indicated and requires dilation and curettage. In addition to UAE, the risk of hemorrhage may also be reduced by transvaginal ligation of the cervical branches of the uterine arteries, cervical cerclage, or intracervical vasopressin injection. Postoperative bleeding can often be controlled with tamponade using a Foley catheter, hemostatic sutures in the implantation site, UAE, bilateral uterine or internal iliac artery ligation, or hysterectomy. Data on future pregnancy outcomes after cervical ectopic pregnancy are limited. Hysterectomy may be considered as an initial option in women who have completed their childbearing.

 

Further reading:

 

Original approval January 2014; Revised May 2017, Reaffirmed November 2018

 

********** Notice Regarding Use ************

 The Foundation for Exxcellence in Women’s Health, Inc (“Foundation”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.

This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.

Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The Foundation reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. The Foundation does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither the Foundation, the ABOG, SASGOG nor their respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Copyright 2018 The Foundation for Exxcellence in Women's Health, Inc. All rights reserved.  No re-print, duplication or posting allowed without prior written consent.

Back to Search Results